Placebo News and Research

RSS

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology.

18 Dec 2013

Selenium fails to protect NSCLC patients against second primary tumors

Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say.

17 Dec 2013

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush).

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

MicroBiome Therapeutics announces completion of $1.3M bridge financing

MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

16 Dec 2013

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Anastrozole drug reduces breast cancer in high risk post-menopausal women

Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study published in the Lancet today.

13 Dec 2013

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet.

13 Dec 2013

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Retrophin, Inc. today announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties.

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

12 Dec 2013

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

Absorption Pharmaceuticals LLC in collaboration with Kaiser Permanente announced today the initiation of a clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation. This Phase III, double blind, placebo-controlled, randomized study will measure the intravaginal ejaculatory latency time for subjects aged 18 and older.

11 Dec 2013

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.

11 Dec 2013

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease Extension trial.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.

11 Dec 2013

Placebo News and Research

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Selenium fails to protect NSCLC patients against second primary tumors

Oral garlic does not reduce vaginal thrush, study finds

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

MicroBiome Therapeutics announces completion of $1.3M bridge financing

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Anastrozole drug reduces breast cancer in high risk post-menopausal women

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News